Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD200AR-L and GBM6-AD Vaccine for Pediatric Glioma
NCT06305910Phase 1Recruiting
- Sponsor
- OX2 Therapeutics
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hP1A8 in high-grade glioma (HGG), diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), sponsored by OX2 Therapeutics. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
hP1A8
03
Conditions
high-grade glioma (HGG)diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT06305910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305910.